Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in Non-Metastatic CRPC with Elevated Chromogranin A
NCT01313273Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in prostate cancer (PCa), sponsored by Ipsen. Started Jun 2011; status: terminated.
02
Drugs
lanreotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01313273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313273.